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Peptide Acts as an Agonist for P2X7
Lucˇka Bibicˇ and Leanne Stokes*
School of Pharmacy, University of East Anglia, Norwich, United Kingdom
The P2X7 receptor (P2X7) is a cell surface ligand-gated ion channel, activated by its
physiological nucleotide agonist ATP and a synthetic analog (BzATP). However, it has
also been suggested that there may be structurally unrelated, non-nucleotide agonists
such as the amyloidogenic β peptide. Here we aimed to reassess the effect of amyloid
β peptides in various in vitro cell models, namely HEK293 overexpressing human P2X7,
the microglial BV-2 cell line, and BV-2 cells lacking P2X7. We measured YO-PRO-1
dye uptake in response to full-length amyloid β peptide (1–42) or the shorter amyloid
β peptide (25–35) and there was a concentration-dependent increase in YO-PRO-1
dye uptake in HEK-hP2X7 cells. However, these amyloid β peptide-induced increases
in YO-PRO-1 dye uptake were also identical in non-transfected HEK-293 cells. We
could observe small transient increases in [Ca2+]i induced by amyloid β peptides in
BV-2 cells, however these were identical in BV-2 cells lacking P2X7. Furthermore, our
metabolic viability and LDH release experiments suggest no significant change in viability
or cell membrane damage in HEK-hP2X7 cells. In the BV-2 cells we found that high
concentrations of amyloid β peptides (1–42) and (25–35) could reduce cell viability by
up to 35% but this was also seen in BV-2 cells lacking P2X7. We found no evidence of
LDH release by amyloid β peptides. In summary, we found no evidence that amyloid β
peptides act as agonists of P2X7 in our in vitro models. Our study raises the possibility
that amyloid β peptides simply mimic features of P2X7 activation.
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INTRODUCTION
The most prevalent cause of dementia is Alzheimer’s disease, a fatal neurodegenerative disorder that
is characterized by a progressive cognitive and functional impairment and memory loss (Heppner
et al., 2015). In the field of Alzheimer’s disease research, the amyloid cascade hypothesis has been
the major hallmark of pathogenesis. This states that the generation of amyloid plaques, primarily
composed of the amyloid-β peptide (Aβ), represents the initial event triggering neurobiological
dysfunction (Hardy and Selkoe, 2002). Over two decades of research (Hardy and Higgins, 1992)
have recently revealed many layers of complexity (Lee et al., 2018), however, the bulk of data still
supports the role of the Aβ peptide as the primary initiator of Alzheimer’s disease pathogenesis
(Musiek and Holtzman, 2015; Cheignon et al., 2018).
Previous data have indicated that the immune system may have a role in Alzheimer’s
disease and that activated microglia have been observed in patients (Sarlus and Heneka, 2017).
Microglia, the resident macrophages of the CNS, alter their morphology and phenotype to adopt
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a so-called activated state in response to neurophysiological
brain insults (Heneka et al., 2015; Sarlus and Heneka, 2017).
Morphologically activated microglia are believed to contribute
to the progression of Alzheimer’s disease via receptors such
as the scavenger receptor CD36 (El Khoury et al., 1996),
α6β1 integrins (Koenigsknecht and Landreth, 2004), the formyl
peptide receptor-like protein (Le et al., 2001), TLR2 (Chen et al.,
2006), TLR4 (Michaud et al., 2013) and the TLR-interacting
molecule CD14 (Fassbender et al., 2004). As a result, this leads to
inflammatory mediator secretion and microglial responsiveness
to injury as comprehensively reviewed by Sarlus and Heneka
(2017). However, another receptor that is also highly expressed
by microglial cells is P2X7, an ATP-gated ion channel (Chessell
et al., 1997; Ferrari et al., 1997; Bartlett et al., 2013). In
recent years, several studies suggested the participation of P2X7
in Aβ-mediated brain damage (Haughey and Mattson, 2003;
Parvathenani et al., 2003; Rampe et al., 2004; McLarnon et al.,
2006). Furthermore, Sanz et al. (2009) suggested that P2X7 may
participate in microglia activation by Aβ peptides and it has
since been proposed that ATP might not be the only endogenous
agonist for P2X7 receptors (Di Virgilio et al., 2018). This may, in
turn, open new avenues for the development of novel therapies
for Alzheimer’s disease. Intrigued by this proposal of alternative
agonists, we set out to determine if Aβ could act as a P2X7 agonist
and investigate the effect of positive allosteric modulators of P2X7
that we have previously characterized (Helliwell et al., 2015).
However, we have been unable to validate the results that suggest
that Aβ-induced responses require the expression of P2X7. Based
on our data, we conclude that Aβ peptides may not directly cause
P2X7-dependent signaling in microglial cells.
MATERIALS AND METHODS
Cell Culture
Microglial BV-2 and BV-2 P2X7-deficient cells were maintained
in DMEM/F12 with L-glutamine (Gibco 11320-074, Fisher
Scientific, United Kingdom), containing 10% (v/v) FBS (Gibco,
US origin), penicillin and streptomycin (Fisher Scientific,
United Kingdom). HEK-293 cells were maintained under the
same media conditions. HEK-293 cells stably expressing human
P2X7 were generated previously (Bhaskaracharya et al., 2014)
and maintained under similar conditions with the addition
of 400 µg/ml geneticin (Fisher Scientific, United Kingdom).
All cells were maintained at 37◦C with 5% CO2 in a
humidified incubator.
Materials
Aβ peptides corresponding to human Aβ amino acids Aβ25−35,
Aβ35−25 (inactive scrambled peptide) and Aβ1−42 were
purchased from GenScript, United States and prepared as
10 mM stock solutions in either water or DMSO. Apyrase (an
ATP-hydrolyzing enzyme), ATP and BzATP were purchased
from Sigma Aldrich, United Kingdom. Stock solutions of P2X7
antagonists AZ10606120 and JNJ47965567 (Tocris Bioscience,
Bio-Techne, United Kingdom) were prepared in DMSO (10 mM)
and stocks were kept frozen at−20◦C.
Measurements of Intracellular Ca2+
The cells were seeded at 2 × 105 cells/well (100 µl) and plated
on poly-D-Lysine coated 96-well plates (Nunc 167008, Fisher
Scientific, United Kingdom) and used for experiments 24 h after
plating. Cells were loaded with the indicator dye Fura-2-AM
using a concentration of 2 µM (HelloBio, United Kingdom) in
HBSS for 45 min at 37◦C. Loading buffer was removed and
replaced with 180 µl of assay buffer containing 147 mM NaCl,
2 mM KCl, 0.1 mM CaCl2, 13 mM Glucose, 10 mM HEPES;
pH 7.35. The plate was warmed in the FlexStation 3 (Molecular
Devices, United Kingdom) for 10 min before recording using
excitation wavelengths 340 and 380 nm and emission at 520 nm
(Bibic et al., 2019).
Agonists (10x concentration) were automatically injected at
30 s using the Flex function. Data was converted to Fura-2
ratio (340/380) and normalized using a zero baseline correction.
Area under the curve was calculated and plotted. All data was
collected in triplicate.
Measurements of YO-PRO-1 Dye Uptake
Impermeant dye uptake was measured with the extracellular
fluorescent tracer YO-PRO-1, a probe that enters the cells
through P2X7 activation-induced pores and emits fluorescence
when it binds DNA (Idziorek et al., 1995). A solution of 2 µM
YO-PRO-1 in assay buffer (see above) was added to wells, and
the 96-well plate was placed at 37◦C for 10 min. The fluorescence
signal in response to drug injection was then measured using a
Flexstation 3 (Molecular Devices) as described previously (Bidula
et al., 2019; Dhuna et al., 2019). Excitation wavelength was 490
nm and emission was measured at 520 nm. Machine settings
include bottom read fluorescence, PMT medium, 6 reads/well
with a sample interval of 3.5 s. RFU data was normalized using a
zero baseline correction and area under the curve was calculated
and plotted. All data was collected from triplicate wells in each
independent experiment.
Cell Viability Measurements
Cells were plated at 2 × 104/well (in a volume of 100 µl)
and plated on non-coated 96-well plates (Fisher Scientific,
United Kingdom) in culture medium containing 1% FBS 24
h before stimulation. Stimuli included concentrations of Aβ
peptides (10–60 µM), ATP at 500 µM and 3 mM concentrations,
as well as staurosporine (5 µM), and the vehicle control (DMSO).
Following incubation with different stimuli, resazurin (0.1 mg/ml
in PBS, Sigma Aldrich) was added to cells for final 2 h at 37◦C.
The plate was then read on a Flexstation 3 plate reader using an
excitation wavelength of 570 nm and emission wavelength of 600
nm (Bidula et al., 2019).
LDH Release Assay
Lactate dehydrogenase (LDH) release into cell culture
supernatants was measured using an LDH assay kit (Pierce,
Fisher Scientific, United Kingdom) following the manufacturer’s
instructions. Control cells were lysed with the lysis buffer
provided to harvest total intracellular LDH. For measuring LDH
release, cells were cultured in 96-well plates, stimuli applied for
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24 h, and supernatants were collected. Absorbance of duplicate
50 µl aliquots of supernatants were measured on a Flexstation 3
plate reader at 490 nm.
Data Analysis and Statistics
All results are expressed as mean ± SD using data from collated
experiments. All experimental data was collected from triplicate
wells. All data for cell viability and cytotoxicity were obtained
as relative fluorescence units (RFU) and are expressed as a
percentage of the negative control (culture medium). Statistical
analysis was performed using one-way ANOVA followed by
Tukey’s multiple comparison post-hoc test (GraphPad Prism v8).
Statistically significant differences from controls are indicated by
∗ using p< 0.05 as a threshold.
RESULTS
A study using N13 microglial cells indicated that Aβ peptide,
both the full-length 1–42 and the shorter 25–35, may induce
responses similar to the activation of P2X7 (Sanz et al., 2009).
We show that stimulation of BV-2 microglial cells with ATP and
BzATP, both known agonists for P2X7, led to [Ca2+]i increases
(Figures 1A,C). Using a P2X7-deficient BV-2 cell line generated
by CRISPR/Cas9 gene editing (Dhuna et al., 2019), the [Ca2+]i
responses were different to the parental BV-2 line, with the
response to BzATP almost completely abolished (Figures 1B,D).
We first tested Aβ25−35 and found that this peptide did
induce a transient increase in [Ca2+]i increase in BV-2 cells
(Figures 1A,E) that displayed a concentration-dependent effect.
We observed a similar Aβ25−35 -induced [Ca2+]i increase in the
P2X7-deficient BV-2 cells (Figures 1B,F). Furthermore, we show
that the Aβ25−35 induced [Ca2+]i increases were not affected
by the P2X7-selective antagonist AZ10606120 whereas the ATP-
induced [Ca2+]i increase was reduced 30% by AZ10606120
(Figure 1A) in BV-2 cells. As expected, there was no significant
effect of AZ10606120 in P2X7-deficient BV-2 cells (Figure 1B).
The inactive scrambled Aβ35−25 peptide did not increase [Ca2+]i
to the same level as Aβ25−35 in BV-2 microglial cells, whether
expressing P2X7 (Figure 1G) or not (Figure 1H). Some evidence
suggests that the solvent, such as DMSO, acetonitrile, and water,
may influence the self-assembly and thus the biological activity
of Aβ peptides (Busciglio et al., 1992; Shen and Murphy, 1995;
Zagorski et al., 1999). In our experiments Aβ25−35 was prepared
in either DMSO or water (Figure 1) and peptide dissolved in
DMSO displayed higher Aβ25−35 -induced [Ca2+]i increases
(Figures 1E,F and Supplementary Figure S1).
We next tested whether Aβ25−35 would induce responses in
a stable HEK-293 cell line over-expressing human P2X7 (HEK-
hP2X7). We used a standard YO-PRO-1 dye uptake assay to
assess the P2X7 large pore formation (Bibic et al., 2019). We
observed that Aβ25−35 (Figures 2A,B), but not the inactive
scrambled Aβ35−25 (Figure 2C), induced a significant YO-PRO-
1 uptake over the concentration range 30–100 µM. Notably, this
Aβ25−35-induced dye uptake was not abrogated by the P2X7-
specific antagonist AZ10606120 despite complete blockade of
ATP- and BzATP-induced dye uptake in this cell line (Figure 2A).
Furthermore, Aβ25−35-induced dye uptake was not affected by
the ATP-degrading enzyme apyrase (Supplementary Figure S2).
In addition, we observed that Aβ25−35 induced YO-PRO-1 dye
uptake into non-transfected HEK-293 cells which fail to display
ATP-induced dye uptake (Figure 2D) supporting the hypothesis
that the observed effects of Aβ25−35 are not dependent on the
expression of P2X7. The inactive scrambled Aβ35−25-peptide did
not induce YO-PRO-1 dye uptake responses (Figures 2B,C). The
Aβ25−35-induced dye uptake was affected by the solvent used
with the DMSO-peptide having a greater effect than the water-
solubilized peptide (Figure 2B and Supplementary Figure S2).
We investigated the full-length Aβ peptide, 1–42, which
was also reported by Sanz et al. (2009) to have an effect on
microglial IL-1β secretion. We did not observe [Ca2+]i increases
in BV-2 (Figure 3A) or YO-PRO-1 dye uptake in HEK-hP2X7
(Figure 3B) in response to Aβ1−42 peptide at concentrations
of 10, 60 or 100 µM. Both ATP and BzATP induced robust
responses in both cell lines and the P2X7-selective antagonists
AZ10606120 and JNJ47965567 could abolish these responses
(Figure 3). Even at the highest concentration of Aβ1−42, this
peptide did not cause a significant increase in [Ca2+]i release
relative to the buffer control.
Once activated, P2X7 is endowed with the ability to kill
microglia, either by necrosis or apoptosis, as well as to trigger
many responses such as inflammation and oxidative stress
(Surprenant et al., 1996; Ferrari et al., 1997; Brough et al., 2002;
Volonte et al., 2012). Thus, we examined whether Aβ25−35 or
Aβ1−42 could trigger cell death in BV-2, P2X7-deficient BV-2
cells, or HEK-hP2X7 cells at either 10, 30 or 60 µM, using a
cell viability assay (Figure 4). In BV-2 (Figure 4A) and P2X7-
deficient BV-2 cells (Figure 4B), Aβ1−42 or Aβ25−35 (60 µM)
reduced cell viability similarly up to 35 and 30% of control,
respectively, suggesting that this effect was not P2X7 dependent.
Lower concentrations of Aβ1−42 or Aβ25−35 (10, 30 µM) had
lesser effects and no significant decrease in cell viability was found
with Aβ1−42 or Aβ25−35 on HEK-hP2X7 cells (Figure 4C). The
inactive scrambled Aβ35−25 peptide did not have any effect on
the cell viability (Figures 4A–C). Cell supernatants were also
measured for the presence of LDH, which is released upon
cell lysis. Figures 4D–F shows LDH levels from BV-2 cells,
P2X7-deficient BV-2 cells, and HEK-hP2X7 cells. None of the
Aβ-treated HEK-hP2X7 cell supernatants contained significant
levels of released LDH as compared with control samples of
cells stimulated with staurosporine or 3 mM ATP. In the BV-2
cells and P2X7-deficient BV-2 cells, we found a relatively high
spontaneous LDH release and none of the Aβ peptide treatments
were higher than this (Figures 4D,E).
DISCUSSION
ATP is a crucial extracellular messenger serving as the
physiological agonist of both P2Y and P2X receptors (Wang
et al., 2004; Davalos et al., 2005; Haynes et al., 2006; Koizumi
et al., 2007). The identification of alternative agonists for P2X
receptors is of particular interest when ascribing physiological
roles to individual receptors in different cells and tissues. There
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FIGURE 1 | Aβ25−35 induced similar [Ca2+]i responses in microglial BV-2 cells in the presence/absence of P2X7. BV-2 cells were loaded with Fura-2AM (2 µM) and
challenged with the Aβ25−35 peptides (DMSO) in the concentration range 30–100 µM in either BV-2 (A) or P2X7-deficient BV-2 (B). One-way ANOVA was
performed with Tukey’s multiple comparison test where * indicates a significant difference to the paired control (with AZ1060610) and ns denotes no significant
difference. Each symbol represents a single well and data has been collated from all independent experiments. Kinetics of the [Ca2+]i response in either BV-2 (C,E)
or P2X7-deficient BV-2 (D,F) are plotted from a representative experiment. Similarly, BV-2 cells were loaded with Fura-2AM (2 µM) and challenged with the inactive
scrambled Aβ35−25 peptide in the concentration range 30 µM -100 µM in either BV-2 (G) or P2X7-deficient BV-2 (H). AZ10606120 is a selective antagonist of
P2X7, and BzATP is a synthetic agonist for P2X7 receptors. Experiments were repeated five times with triplicates on each plate, and the results are presented as
area under curve (mean ± SD). One-way ANOVA was performed with Tukey’s multiple comparison test where * indicates a significant difference (P < 0.05) to the
control (buffer alone) and ns denotes no significant difference.
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FIGURE 2 | Aβ peptides triggered a non-specific YO-PRO-1 uptake in HEK-hP2X7 and HEK-293 cells. HEK-hP2X7 and plain HEK-293 cells were incubated with
YO-PRO-1 dye in low-divalent assay buffer (2 µM) and challenged with either Aβ25−35 (A,B) or the inactive scrambled version Aβ35−25 (C). Kinetics of the Aβ25−35
dye uptake response in HEK-hP2X7 are plotted together with the appropriate controls (B). AZ10606120 is a selective antagonist of hP2X7, and BzATP is a synthetic
agonist for hP2X7 receptors. (D) shows summary data from HEK-293 cells comparing responses to HEK-hP2X7 cells. Experiments were repeated five times with
triplicates on each plate, and the results are presented as mean ± SD. One-way ANOVA was performed with Tukey’s multiple comparison test where * indicates a
significant difference (P < 0.05) to the paired control [with AZ1060610 in (A) or control in (C)] and ns denotes no significant difference.
has been a suggestion that ATP may not be the only agonist at
P2X7 receptors (Di Virgilio et al., 2018). It is proposed that agents
such as amyloid–β (Sanz et al., 2009), serum amyloid (Niemi
et al., 2011) and the cathelicidin LL-37 peptide (Elssner et al.,
2004), may function as non-nucleotide agonists at P2X7. In the
current study, we revisited the role of the amyloid-β peptide as
an agonist for the P2X7 receptor using a microglial cell line and
HEK-293 cells over-expressing human P2X7. We have previously
used the microglial BV-2 cells and a clonal P2X7-deficient BV-
2 cell line, generated using Cas9 gene editing, in order to assess
Ca2+ influx upon P2X7 activation with ATP and the effect of
positive modulators (Dhuna et al., 2019).
The biological effect of synthetic amyloid-β peptides,
including Aβ25−35, may vary due to differences in aggregation
states (Pike et al., 1993; Wei and Shea, 2006), therefore we
performed the experiments using two common solvents, DMSO
(Mattson et al., 1993) and water (Whitson et al., 1994). Our
data shows that Aβ25−35 directly induced intracellular Ca2+
responses in BV-2 microglial cells regardless of the solvent
(Figure 1) although responses were noted to be higher for the
DMSO-dissolved peptide. We saw no increase in [Ca2+]i to
the full length human Aβ1−42 peptide. Furthermore, when
these two amyloid-β peptides (Aβ25−35 and Aβ1−42) were
studied in a HEK-hP2X7 stable cell line using a dye uptake
assay (Helliwell et al., 2015; Bibic et al., 2019; Bidula et al.,
2019; Dhuna et al., 2019), we observed some YO-PRO-1 dye
uptake in response to Aβ25−35. However, this also occurred
in non-transfected HEK-293 cells that do not express P2X7
receptors (Figure 2). We saw no increase in YO-PRO-1 dye
uptake to the full length human Aβ1−42 peptide. Collectively
this data suggests that amyloid-β peptides may act on other
receptors that can induce similar responses to P2X7 or the
peptide may act by insertion into the lipid bilayer forming
similar pores. It is known that other agents such as maitotoxin
and ionomycin can induce dye uptake responses to P2X7
stimulation (Schilling et al., 1999; Verhoef et al., 2004)
likely through insertion into the membrane and subsequent
pore formation. There is evidence that amyloid-β peptides
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FIGURE 3 | Aβ1−42 do not trigger responses in BV-2 cells or HEK-hP2X7 cells. BV-2 cells were loaded with Fura-2AM (2 µM) and challenged with the Aβ−1−42 (A)
peptides in the concentration range 30–100 µM. HEK-hP2X7 cells were exposed to YO-PRO-1 dye in low-divalent assay buffer (2 µM) and challenged similarly as
BV-2 cells (B). AZ10606120 is a commercially available antagonist of hP2X7. Experiments were repeated five times with triplicates on each plates, and the results
are presented as mean ± SD. One-way ANOVA was performed with Tukey’s multiple comparison test where * indicates a significant difference (P < 0.05) to the
control (buffer alone) and ns denotes no significant difference.
FIGURE 4 | Aβ peptides do not trigger P2X7-specific cell death nor compromise the cell membrane in microglial BV-2 cells or HEK-hP2X7 cells. (A–C) An
AlamarBlue assay and (D–F) an LDH assay were performed to assess cell viability and cell death respectively after 24 h administration of Aβ peptides. At indicated
times (see “Materials and Methods”), the extracellular medium was collected and assayed for lactate dehydrogenase (LDH) activity. Control cells were lysed with the
lysis buffer to induce maximal LDH release for normalization of the LDH release (% of max). Staurosporine and 3 mM ATP were used as a positive control. Data
points represent the mean ± SD of 5 replicated experiments with triplicates on each plate. One-way ANOVA was performed with Dunnett’s multiple comparison test
where * indicates a significant difference (P < 0.05) to the control (media alone).
may act via other routes such as on pannexin-1 (Orellana
et al., 2011) to cause ATP release from cells rather than
acting to directly activate P2X7. This was also suggested
to be the likely (indirect) effect on microglial cells in the
work by Sanz et al. (2009). We did not directly measure
ATP release in our study but we hypothesized that any ATP
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released by the amyloid-β peptides would elicit responses at P2X
receptors and therefore we would have seen an effect of the
P2X7-selective antagonists, apyrase, or in the BV-2 cells with
P2X7 deficiency.
Human and rodent (rat/mouse) full length amyloid-β peptide
(1–42) are highly similar and differ only in three amino
acid substitutions at the N-terminus. It is not clear which
isoform of the Aβ1−42 was used in the study by Sanz et al.
(2009) however, we believe this minor sequence difference is
unlikely to contribute to our lack of effect at P2X7. Indeed,
should there be a species difference, we would expect to see
responses at human P2X7 (which we did not). The amino
acid sequence for Aβ25−35 peptide is identical between human
and rodent. In our study we focused on addressing whether
the amyloid-β peptides could act as agonists at P2X7. We
did not extend our experiments to investigate the effect of
amyloid-β peptides on IL-1β secretion from microglial cells.
Gustin et al. demonstrated that Aβ25−35 could induce IL-1β
secretion from LPS-primed mouse microglia but did not detect
any ATP secretion in response to Aβ25−35. Furthermore, this
team of researchers used primary microglia from the P2X7−/−
mouse and observed a similar IL- 1β secretion in response to
Aβ25−35 (Gustin et al., 2015). This notion led them to conclude
that Aβ25−35-induced IL-1β secretion was P2X7-independent
(Gustin et al., 2015). This contradicts the earlier work from
Sanz et al. who demonstrated that amyloid peptides could
induce IL-1β release from primary microglia but only when
P2X7 was present (Sanz et al., 2009). Furthermore, in vivo
evidence showed that amyloid β-induced IL-1β secretion in the
hippocampus was reduced in P2X7 knockout mice (Sanz et al.,
2009). Other studies have shown that activation of microglia
with Aβ1−42, followed by exposure to BzATP, may result in
enhanced secretion of IL-1β (Rampe et al., 2004). This suggests
that amyloid-β peptides may be working as positive allosteric
modulators rather than as agonists. Furthermore, McLarnon
et al. demonstrated that Ca2+ responses in adult microglial cells
from Alzheimer’s disease patients were significantly increased
following Aβ1−42 pre-treatment when activated by a P2X7
selective agonist BzATP (McLarnon et al., 2006). We have tested
the idea that amyloid-β peptides could act as positive allosteric
modulators since this was our entry point into this set of
experiments. However, we saw no enhancement of ATP-induced
[Ca2+]i responses by Aβ1−42 peptide and no potentiation
of ATP-induced YO-PRO-1 dye uptake in HEK-hP2X7 cells
(Supplementary Figure S3).
Microglial cell death (measured as a reduction in cellular
viability) can be observed when cells were stimulated by 3 mM
ATP (Nishida et al., 2012; Dhuna et al., 2019). When the
BV-2 cells were stimulated by either Aβ1−42, Aβ25−35 or the
inactive scrambled Aβ35−25 peptide (60 µM), microglial cell
viability was reduced by 35% compared to control. There
was no significant increase in LDH release above vehicle
treatment or spontaneous LDH release induced by water. Our
data indicate that Aβ peptides may not act as non-nucleotide
agonists of the P2X7 receptor and that Aβ peptides are unable
to induce cytotoxicity or decrease cell viability directly via
P2X7. We are not discarding P2X7 as an emerging therapeutic
target for Alzheimer’s disease. Others have shown that P2X7
is involved in amyloid protein precursor (APP) processing
(Delarasse et al., 2011) and affects phagocytosis of Aβ peptides
(Ni et al., 2013). More recently, the P2X7 knockout mouse
was investigated in the APPPS1 mouse model of Alzheimer’s
disease (Martin et al., 2019). P2X7−/−mice had a reduced
amyloid-β load and were protected from cognitive defects.
In this model the chemokines CCL3, CCL4, and CCL5 were
elevated only when P2X7 was present and this affected CD8+
T cell recruitment to the choroid plexus and hippocampus
(Martin et al., 2019). It appears that there is still more to be
discovered about how P2X7 can influence the development of
neurodegenerative disorders.
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